Why the study?
Advances in metabolomics and lipidomics have better characterized heart failure pathologies, prompting an overview of cardiac metabolism and the metabolic effects of heart failure drugs.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Metabolic insights into SGLT2i mechanisms in HF; extends understanding while leaving open clinical translation.
Cardiovascular disease is the leading cause of mortality globally with at least 26 million people worldwide living with heart failure (HF). Metabolism has been an active area of investigation in the setting of HF since the heart demands a high rate of ATP turnover to maintain homeostasis. With the advent of -omic technologies, specifically metabolomics and lipidomics, HF pathologies have been better characterized with unbiased and holistic approaches. These techniques have identified novel pathways in our understanding of progression of HF and potential points of intervention. Furthermore, sodium-glucose transport protein 2 inhibitors, a drug that has changed the dogma of HF treatment, has one of the strongest types of evidence for a potential metabolic mechanism of action. This review will highlight cardiac metabolism in both the healthy and failing heart and then discuss the metabolic effects of heart failure drugs.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: